MedTrace Logo

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

NCT05873751 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1307378

Last updated 2025-04-17

Study results available
· View outcomes & findings →

Summary

Brief Summary:

The main purpose of the study is to learn about how well Trumenba vaccine shot works against gonorrhea infection.

This study looks at data records from a database in the United States.

This study includes patient's data from the database who:

* Are 15-30 years old.
* Have received at least one dose of Trumenba and a MenACWY vaccine or who have received only MenACWY vaccine.

This data has already been collected in the past and is being studied between April and June of 2023.

Conditions

  • Gonorrhea
  • Chlamydia
  • Meningococcal Vaccines

Interventions

BIOLOGICAL

Trumenba Vaccine

Trumenba vaccine given as standard of care

BIOLOGICAL

MenACWY Vaccine

MenACWY Vaccine given as standard of care

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
15 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-24
Primary Completion
2024-03-31
Completion
2024-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05873751 on ClinicalTrials.gov